Browse Drug Recalls
8 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 8 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 8 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jun 2, 2025 | LIDOcaine HCL Sterile Injection, USP, 20 mg/mL, 2%, (200 mg/10 mL), For Infil... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Jun 2, 2025 | LIDOcaine HCl Injection, USP, 10mg/mL, 1% (100 mg/10mL), 10 mL Sterile Single... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Jun 2, 2025 | BUPIVAcaine HCL Sterile injection, USP w/EPINEPHRINE 1:200,000, 50 mg/10mL, 0... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Jun 2, 2025 | KETAmine Hydrochloride Injection, USP, 500mg/5mL, (10mg/mL), For IM or Slow I... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Jun 2, 2025 | LIDOcaine HCL Sterile Injection, USP, 100mg/10mL, 1%, (10mg/mL), w/EPINEPHRIN... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Jun 2, 2025 | KETAmine Hydrochloride Injection, USP, 50 mg/5mL (10 mg/mL), For IM Use or Sl... | Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufa... | Class II | Tailstorm Health INC |
| Nov 6, 2024 | BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syr... | Lack of Sterility Assurance | Class II | Tailstorm Health INC |
| Jul 3, 2024 | Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:20... | Subpotent Drug: reduced efficacy for epinephrine | Class II | TAILSTORM HEALTH INC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.